Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan + Pertuzumab + Iparomlimab/Tuvonralimab in HER2-Expressing Biliary Tract Cancer
NCT07129018Phase 2Not yet recruiting
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of trastuzumab rezetecan, iparomlimab + tuvonralimab in biliary tract cancer (BTC). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
trastuzumab rezetecaniparomlimab + tuvonralimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07129018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07129018.